# Beam Therapeutics

- **Section**: news
- **Answer**: Beam Therapeutics: 9 headlines on record, 4 headlines in the last 90 days. Its story counts 2 milestones.
- **As of**: 2026-11-17
- **Cite**: Beam Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/beamtx/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 1884200
- **Name**: Beam Therapeutics
- **Domain**: beamtx.com
- **Url**: <https://alion.io/company/beamtx>

## Figures

- Label: Headlines; Value: 9
- Label: In 90 days; Value: 4
- Label: Milestones; Value: 2

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 9
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 2

## News

- [Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows](https://finance.yahoo.com/healthcare/articles/beam-therapeutics-beam-stock-could-011418212.html) — Date: 2026-09-24; Kind: News; Source: YahooFinance
- [Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View](https://seekingalpha.com/article/4945639-beam-therapeutics-market-selling-phase-2-aatd-data-is-understandable-in-my-view) — Date: 2026-09-11; Kind: News; Source: seekingalpha.com
- [Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026](https://markets.businessinsider.com/news/stocks/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026-1036527840) — Date: 2026-09-08; Kind: News; Source: markets.businessinsider.com
- [Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences](https://markets.businessinsider.com/news/stocks/beam-therapeutics-to-participate-in-upcoming-september-2026-investor-conferences-1036507106) — Date: 2026-08-31; Kind: News; Source: markets.businessinsider.com
- [Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.](https://fool.com/coverage/filings/2026/04/11/beam-therapeutics-ceo-sold-over-30-000-company-shares-here-s-what-this-means-for-investors/) — Date: 2026-04-11; Kind: News; Source: The Motley Fool
- [Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential](https://seekingalpha.com/article/4831867-beam-therapeutics-scd-catalysts-have-untapped-upside-potential) — Date: 2025-10-22; Kind: News; Source: seekingalpha.com
- [Why Beam Therapeutics Stock Tanked on Tuesday](https://nasdaq.com/articles/why-beam-therapeutics-stock-tanked-tuesday) — Date: 2025-05-05; Kind: News; Source: Nasdaq
- [Beam Therapeutics to Report Q1 Earnings: What](https://nasdaq.com/articles/beam-therapeutics-report-q1-earnings-whats-cards) — Date: 2025-04-24; Kind: News; Source: Nasdaq
- [Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease](https://benzinga.com/25/04/44667267/beam-therapeutics-presents-biomarker-data-for-beam-302-gene-therapy-for-inherited-disease) — Date: 2025-04-07; Kind: News; Source: benzinga.com

## Story

- [Board appointment Robert Nelsen, Director · SEC Form D](https://www.sec.gov/Archives/edgar/data/1745999/000174599919000002/)
- **Founded**

---
[Page](https://alion.io/company/beamtx/news) · [JSON](https://alion.io/company/beamtx/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
